Denaturing-HPLC-Based Assay for Detection of ABL Mutations in Chronic Myeloid Leukemia Patients Resistant to Imatinib

Despite the efficacy of the BCR-ABL tyrosine kinase inhibitor Imatinib mesylate for the treatment of chronic myeloid leukemia (CML), resistance has been observed in a proportion of cases, especially those with advanced stages of the disease. Point mutations within the ABL kinase domain are emerging...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical chemistry (Baltimore, Md.) Md.), 2004-07, Vol.50 (7), p.1205-1213
Hauptverfasser:	Soverini, Simona, Martinelli, Giovanni, Amabile, Marilina, Poerio, Angela, Bianchini, Michele, Rosti, Gianantonio, Pane, Fabrizio, Saglio, Giuseppe, Baccarani, Michele
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino acids Analytical, structural and metabolic biochemistry Antineoplastic Agents - therapeutic use Benzamides Biological and medical sciences Bone marrow Chromatography, High Pressure Liquid - methods DNA Mutational Analysis Drug Resistance, Neoplasm Fundamental and applied biological sciences. Psychology Fusion Proteins, bcr-abl Genes, abl Hematologic and hematopoietic diseases Humans Imatinib Mesylate Investigative techniques, diagnostic techniques (general aspects) Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Liquid chromatography Medical sciences Molecular biophysics Mutation Piperazines - therapeutic use Point Mutation Protein-Tyrosine Kinases - genetics Pyrimidines - therapeutic use Retrospective Studies Reverse Transcriptase Polymerase Chain Reaction Sensitivity and Specificity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!